Cargando…

CTTN Overexpression Confers Cancer Stem Cell-like Properties and Trastuzumab Resistance via DKK-1/WNT Signaling in HER2 Positive Breast Cancer

SIMPLE SUMMARY: Cortactin (CTTN) is an actin-binding protein that is mainly known for its ability to promote cancer progression. It is unclear, however, whether CTTN affects tumor initiation and anti-tumor drug resistance in breast cancer. Here, we investigated the potential role of CTTN as a novel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moon, So-Jeong, Choi, Hyung-Jun, Kye, Young-Hyeon, Jeong, Ga-Young, Kim, Hyung-Yong, Myung, Jae-Kyung, Kong, Gu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954024/ https://www.ncbi.nlm.nih.gov/pubmed/36831511 http://dx.doi.org/10.3390/cancers15041168

Ejemplares similares

Association of CTTN polymorphisms with the risk of colorectal cancer
por: Lee, Seok Youn, et al.
Publicado: (2012)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
por: Xing, Fei, et al.
Publicado: (2023)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
por: Fiszman, Gabriel L., et al.
Publicado: (2011)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab
por: Sorscher, Steven
Publicado: (2013)

Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
por: Nahta, Rita
Publicado: (2012)

Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells
por: Mann, K, et al.
Publicado: (2016)

Distinct roles of DKK1 and DKK2 in tumor angiogenesis
por: Park, Hongryeol, et al.
Publicado: (2013)

Amplification and overexpression of CTTN and CCND1 at chromosome 11q13 in Esophagus squamous cell carcinoma (ESCC) of North Eastern Chinese Population
por: Hu, Xiaoxia, et al.
Publicado: (2016)

A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer
por: Bussolati, G, et al.
Publicado: (2005)

Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
por: Wu, Yanyuan, et al.
Publicado: (2020)

Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
por: Lee, Yu Rim, et al.
Publicado: (2011)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
por: Nieto, Celia, et al.
Publicado: (2019)

Structural and functional analysis of Dickkopf 4 (Dkk4): New insights into Dkk evolution and regulation of Wnt signaling by Dkk and Kremen proteins
por: Patel, Saleha, et al.
Publicado: (2018)

Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis
por: Park, Joo-Hwan, et al.
Publicado: (2022)

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy
por: Jung, Minkyu, et al.
Publicado: (2012)

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
por: Harder, J, et al.
Publicado: (2012)

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
por: Arteaga, Carlos L
Publicado: (2003)

Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression
por: Aboudaram, Amélie, et al.
Publicado: (2021)

Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma
por: Wei, Chuan-Yuan, et al.
Publicado: (2019)

Genome-Wide Gene Expression Profile Analyses Identify CTTN as a Potential Prognostic Marker in Esophageal Cancer
por: Lu, Pei, et al.
Publicado: (2014)

Hypermethylation of UCHL1 Promotes Metastasis of Nasopharyngeal Carcinoma by Suppressing Degradation of Cortactin (CTTN)
por: Zhao, Yin, et al.
Publicado: (2020)

Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death
por: Le Scodan, Romuald, et al.
Publicado: (2011)

Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore
por: de Lima Lopes, Gilberto
Publicado: (2011)

Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series
por: Di Lauro, Vincenzo, et al.
Publicado: (2012)

Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
por: Nunes, Toni, et al.
Publicado: (2019)

PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2017)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
por: Wang, Lei, et al.
Publicado: (2020)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

Roles of Wnt3a and Dkk1 in experimental periodontitis
por: Liu, Jianqi, et al.
Publicado: (2017)

The HBx–CTTN interaction promotes cell proliferation and migration of hepatocellular carcinoma via CREB1
por: Li, Yajun, et al.
Publicado: (2019)

piR-19166 inhibits migration and metastasis through CTTN/MMPs pathway in prostate carcinoma
por: Qi, Tingyue, et al.
Publicado: (2020)

Psoriasis Induced by Trastuzumab (Herceptin®)
por: Kim, Dae Hun, et al.
Publicado: (2013)

Osthole Synergizes With HER2 Inhibitor, Trastuzumab in HER2-Overexpressed N87 Gastric Cancer by Inducing Apoptosis and Inhibition of AKT-MAPK Pathway
por: Yang, Yun, et al.
Publicado: (2018)

Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
por: Menendez, Javier A, et al.
Publicado: (2007)

Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
por: Lavaud, Pernelle, et al.
Publicado: (2014)

A CT-based radiomics signature for prediction of HER2 overexpression and treatment efficacy of trastuzumab in advanced gastric cancer
por: Ma, Tingting, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kbqf3j2fm266oqdh87et17sioq